Form 8-K - Current report:
SEC Accession No. 0001104659-22-130170
Filing Date
2022-12-27
Accepted
2022-12-27 16:13:44
Documents
13
Period of Report
2022-12-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2233519d1_8k.htm   iXBRL 8-K 43098
2 EXHIBIT 10.1 tm2233519d1_ex10-1.htm EX-10.1 48237
  Complete submission text file 0001104659-22-130170.txt   281970

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kala-20221227.xsd EX-101.SCH 3027
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kala-20221227_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kala-20221227_pre.xml EX-101.PRE 22591
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2233519d1_8k_htm.xml XML 3608
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 221490410
SIC: 2834 Pharmaceutical Preparations